Viswanadhan Krishnan 4
4 · AGIOS PHARMACEUTICALS, INC. · Filed Apr 6, 2026
Research Summary
AI-generated summary of this filing
Agios (AGIO) Chief Corp Dev Krishnan Sells 2,959 Shares
What Happened
Krishnan, Agios Pharmaceuticals' Chief Corporate Development & Strategy officer, had 8,100 performance share units (PSUs) convert into common shares (exercise/conversion reported at $0.00) and sold 2,959 of those shares in an open-market transaction at $34.71 each, netting $102,707. The filing also reports the conversion/settlement of the related derivative award (PSUs).
Key Details
- Transaction date: April 2, 2026. Filing date: April 6, 2026 (filed timely).
- Exercise/conversion: 8,100 shares @ $0.00 (PSUs converted to shares).
- Open-market sale: 2,959 shares @ $34.71 = $102,707.
- Shares owned after the transaction: not disclosed in the filing.
- Notable footnotes: sale of shares was to cover tax withholding on PSU vesting and was effected pursuant to durable automatic sale instructions consistent with a Rule 10b5-1 arrangement (see footnote F1). Each PSU represents a contingent right to one share (F2). The PSUs were granted March 5, 2025; 50% of the award vested upon a specified regulatory milestone determined met on April 2, 2026, and vested shares will be delivered within three business days (F3).
Context
This was a conversion of performance-based equity and a partial sale to satisfy tax withholding obligations under pre-existing automatic instructions — a routine, non-speculative transaction common when awards vest. The $102.7k sale proceeds reflect the tax-withholding sale rather than an outright investment-timing decision.
Insider Transaction Report
- Exercise/Conversion
Common stock
2026-04-02+8,100→ 13,241 total - Sale
Common stock
[F1]2026-04-02$34.71/sh−2,959$102,707→ 10,282 total - Exercise/Conversion
Performance share units
[F2][F3]2026-04-02−8,100→ 8,100 total→ Common stock (8,100 underlying)
Footnotes (3)
- [F1]Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's performance share unit agreement dated March 5, 2025.
- [F2]Each performance share unit represents a contingent right to receive one share of the issuer's common stock.
- [F3]The PSUs were granted on March 5, 2025. The PSUs vest as to 50% of the underlying shares upon the achievement of a specified regulatory milestone and as to the remaining 50% of the underlying shares upon the achievement of a specified commercial milestone. The performance criteria for the specified regulatory milestone was determined to have been met on April 2, 2026, resulting in the vesting of the PSUs as to 50% of the underlying shares. Vested shares will be delivered to the reporting person within three business days after such shares become vested.